BR112018014908A2 - vacina de opioide sintético - Google Patents

vacina de opioide sintético

Info

Publication number
BR112018014908A2
BR112018014908A2 BR112018014908-0A BR112018014908A BR112018014908A2 BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2 BR 112018014908 A BR112018014908 A BR 112018014908A BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2
Authority
BR
Brazil
Prior art keywords
fentanyl
vaccine
drug
analogs
synthetic
Prior art date
Application number
BR112018014908-0A
Other languages
English (en)
Inventor
D. Janda Kim
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of BR112018014908A2 publication Critical patent/BR112018014908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a fentanila é um opioide de prescrição viciante que é mais de 80 vezes mais potente do que a morfina. a natureza sintética da fentanila permitiu a criação de análogos ?fármaco projetado? perigosos que escapam de rastreio de toxicologia, porém exibindo potência comparável ao fármaco parental. de maneira alarmante, um grande número de fatalidades foi ligado à overdose de derivados de fentanila. aqui, a requerente relata uma imunoterapia eficaz para redução dos efeitos psicoativos de fármacos da classe fentanila. uma vacina conjugada única foi criada, a qual elicita níveis altos de anticorpos com reatividade cruzada para um amplo painel de análogos de fentanila. além disso, camundongos vacinados ganharam proteção suficiente de doses de fentanila letais. por fim, uma técnica baseada em ressonância de plásmon de superfície (spr) foi estabelecida permitindo traçado de perfil de especificidade de fármaco de anticorpos derivados diretamente do soro. a vacina de fentanila recém-desenvolvida da requerente e métodos analíticos podem auxiliar na batalha contra abuso de opioide sintético.
BR112018014908-0A 2016-01-21 2017-01-18 vacina de opioide sintético BR112018014908A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (1)

Publication Number Publication Date
BR112018014908A2 true BR112018014908A2 (pt) 2018-12-18

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014908-0A BR112018014908A2 (pt) 2016-01-21 2017-01-18 vacina de opioide sintético

Country Status (8)

Country Link
US (1) US11305010B2 (pt)
EP (1) EP3405475B1 (pt)
JP (1) JP2019506390A (pt)
CN (1) CN108884127A (pt)
BR (1) BR112018014908A2 (pt)
CA (1) CA3015336A1 (pt)
RU (1) RU2018130106A (pt)
WO (1) WO2017127390A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
WO2021092446A1 (en) * 2019-11-08 2021-05-14 Regents Of The University Of Minnesota Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using
CA3167691A1 (en) * 2020-01-13 2021-07-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
US20230126276A1 (en) * 2020-03-13 2023-04-27 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
WO2022240898A1 (en) * 2021-05-10 2022-11-17 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CA2132342A1 (en) 1992-04-06 1993-10-14 Kenneth F. Buechler Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
ES2284783T3 (es) * 2001-11-16 2007-11-16 Randox Laboratories Ltd. Metodo y estuche para detectar, o determinar la cantidad de,metabolitos de fentanilo y metabolitos de analogos de fentanilo.
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
TR201901929T4 (tr) * 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
WO2010120121A2 (ko) * 2009-04-15 2010-10-21 포항공과대학교 산학협력단 표적 특이적 비항체 단백질 및 이의 제조 방법
KR101919170B1 (ko) * 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
CA2895702C (en) 2011-12-21 2020-03-31 The Scripps Research Institute Heroin haptens, immunoconjugates and related uses
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Also Published As

Publication number Publication date
EP3405475B1 (en) 2022-09-28
EP3405475A1 (en) 2018-11-28
CA3015336A1 (en) 2017-07-27
US20210128720A1 (en) 2021-05-06
WO2017127390A1 (en) 2017-07-27
RU2018130106A (ru) 2020-02-21
EP3405475A4 (en) 2019-08-28
US11305010B2 (en) 2022-04-19
CN108884127A (zh) 2018-11-23
RU2018130106A3 (pt) 2020-05-26
JP2019506390A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
BR112018014908A2 (pt) vacina de opioide sintético
BR112017011005A2 (pt) novos indazóis substituídos, métodos para sua produção, preparações farmacêuticas que contêm os novos indazóis substituídos e o uso dos indazóis substituídos para produzir os medicamentos.
Castiglione et al. How the interval between prime and boost injection affects the immune response in a computational model of the immune system
Yoo et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
BR112018003984A2 (pt) anticorpos
Strober et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study.
MX2019013023A (es) Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
MX2019013693A (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
MA50487B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
BR112017015353A2 (pt) inalador de pó seco que compreende propionato de fruticasona e xinafoato de salmeterol
Gillard et al. An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
Chaigne et al. Monoclonal antibodies in excess: A simple way to avoid immunogenicity in patients?
BR112018075422A2 (pt) métodos para tratar ossificação heterotópica
Maurer-Stroh et al. Potential human adaptation mutation of influenza A (H5N1) virus, Canada
Domchek et al. MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumours
Skoromets et al. The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm
Moussa et al. Protective efficacy of immunoglobulins Y prepared against Cerastes cerastes snake venom in the Kingdom of Saudi Arabia.
BR112018015765A2 (pt) Proteína hemaglutinina (ha) modificada do vírus influenza com epítopos heterólogose/ou sítios de clivagem de maturação alterados, vírus influenza modificado, método para a geração de anticorpos, ácido nucleico, células hospedeiras recombinantes, vacina contra gripe e uso da mesma
MA53272A (fr) Procédé de préparation d'une formulation pharmaceutique d'anticorps
Mori et al. Underlying mechanisms of methamphetamine-induced self-injurious behavior and lethal effects in mice
Kostowski et al. Activity of diltiazem and nifedipine in some animal models of depression.
de Liyis et al. Bortezomib in the management of anti-NMDA receptor encephalitis

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements